However, in several diseases, including HD, SCA2, DM1 and C9ORF72 FTD/ALS, both sense and antisense repeats contribute with toxic species, thus targeting both mutant sense and antisense RNAs could be crucial to improving the success of therapies designed to revert the disease phenotype and/or delay disease progression. Here, ATXN2 is linked to myotonic dystrophy type 1.